KROS (Keros Therapeutics) Insider Ownership: 4.46 % (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KROS Keros Therapeutics Inc KROS
51 GF Score
Price $11.47
GF Value $13.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Keros Therapeutics Insider Ownership?

Keros Therapeutics KROS +6.19% 51 Insider Ownership is 4.46 % as of Aug. 25, 2026. GuruFocus rates KROS with a GF Score™ of 51/100 and a GF Value™ of $13.64 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Keros Therapeutics's insider ownership is 4.46%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Keros Therapeutics's Institutional Ownership is 93.17%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Keros Therapeutics's Float Percentage Of Total Shares Outstanding is 86.94%.

Keros Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics Insider Ownership Chart

Keros Therapeutics Historical Data

The historical data trend for Keros Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 1.51 1.70 1.92 2.56 2.56 2.56 2.50 4.23 4.38 4.46
KROS
51GF Score
Keros Therapeutics Inc KROS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 4.46 % mean?
Keros Therapeutics (KROS) has a Insider Ownership of 4.46 % as of Aug. 25, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Keros Therapeutics and its competitors.
Is Keros Therapeutics' Insider Ownership too high?
Keros Therapeutics' current Insider Ownership is 4.46 %. Overall, Keros Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Insider Ownership compare to RNA and NBP?
Keros Therapeutics' Insider Ownership of 4.46 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current Insider Ownership is 4.46 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Keros Therapeutics (KROS) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.64, compared to a current price of $11.47 — trading 15.9% below its estimated fair value. The current Insider Ownership is 4.46 %. Keros Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Insider Ownership is 4.46 % as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Keros Therapeutics (KROS) Overvalued in 2026?

Based on GuruFocus' analysis, Keros Therapeutics stock appears to be undervalued. The current stock price of $11.47 is trading 15.9% below its estimated GF Value™ of $13.64. GuruFocus considers Keros Therapeutics to be Modestly Undervalued.

Key valuation signals for KROS:

  • Insider Ownership: 4.46 %
  • GF Value™: $13.64 vs. price of $11.47 (15.9% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the KROS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
51GF Score

Get the complete analysis for KROS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.47
Price
$13.64
GF Value